IDM Pharma Reports Third Quarter 2007 Financi... (in process research and deve...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

IDM Pharma Reports Third Quarter 2007 Financial Results

Date:11/8/2007

process research

and development - - - -

Total costs and

expenses 9,152,000 7,212,000 26,791,000 24,743,000

Loss from

operations (6,029,000) (4,184,000) (17,712,000) (16,415,000)

Interest income 422,000 118,000 758,000 427,000

Interest expense 2,719,000 - 2,825,000 -

Other income

(expenses), net (23,000) 49,000 (23,000) -

Foreign exchange

gain (loss) (837,000) 165,000 (1,299,000) (1,698,000)

Loss before income

tax benefit (3,748,000) (3,852,000) (15,451,000) (17,686,000)

Income tax benefit

(expense) (5,000) - 87,000 179,000

Net loss $(3,753,000) $(3,852,000) $(15,364,000) $(17,507,000)

Weighted average

number of shares

outstanding 25,146,206 13,398,474 19,703,272 13,354,184

Basic and diluted

loss per share $(0.15) $(0.29) $(0.78) $(1.31)

Comprehensive

loss:

Net loss $(3,753,000) $(3,852,000) $(15,364,000) $(17,507,000)

Other

comprehensive

gain (loss) 1,094,000 (224,000) 1,638,000 2,388,000

$(2,659,000) $(4,076,000) $(13,726,000) $(15,119,000)

IDM PHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

September 30, December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $33,183,000 $10,181,000

Other current assets
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma

Post Your Comments:

(Date:5/21/2013)... Diehard soccer fans will definitely want to see a ... between Manchester City and Chelsea FC at Busch ... teams are highly decorated in the English Premiere League of ... Busch Stadium, home of the St. Louis Cardinals, a professional ... a professional sporting event and non-baseball game will be held ...

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay ... life, but some of the changes brought about by ... diabetes. New research has found that people with ... percent higher risk of having a severe low blood ... compared to people with diabetes who aren,t depressed. ...

(Date:5/21/2013)... Philosophical Society (APS) has awarded New York University neuroscientist ... in recognition of his "pioneering work on the neuroscience ... University,s Center for Neural Science, is the second NYU ... yearsJoseph LeDoux received the honor in 2011 in recognition ... emotional learning, particularly fear learning, and fear memory." ...

(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that their re-launched bike ... achieved its overall goal of becoming a standalone brand. , ... Bicycles from a house brand to a standalone bike brand,” ... that the bike shop will go forward as Switchback ... 29er and 650b. , “The bike shop will ...

(Date:5/21/2013)... major Ohio universities and four hospitals have joined with ... collaborative research program aimed exclusively at finding the unknown ... to invest $10 million in the program over five ... Center -- Ohio Collaborative is a unique research enterprise," ... of Dimes. "This new transdisciplinary, team-based research model will ...

Breaking Medicine News(10 mins):Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2 Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2 Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3 Health News:NYU's Movshon receives Lashley Award for his research on the neuroscience of vision 2 Health News:Hammerhead Bicycles Now a Standalone Brand 2 Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2 Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3

[0] Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO [0] Depression May Raise Low Blood Sugar Risk in Diabetics [0] NYU's Movshon receives Lashley Award for his research on the neuroscience of vision [0] Hammerhead Bicycles Now a Standalone Brand [0] New multi-million dollar research center aims to solve the mystery of premature birth

... Tanaka, president and CEO of Menicon Co., Ltd. ... was appointed as Singapore,s Honorary Consul-General in Nagoya, ... Singapore. The appointment was effective April 20, 2009. ... corporate headquarters in Nagoya.(Photo: http://www.newscom.com/cgi-bin/prnh/20090508/PR34572 ...

... OAK BROOK, Ill., May 7 The University HealthSystem ... 3-year agreement to one supplier, Sodexo Inc., based in ... which has 2 optional 1-year renewal periods, became effective ... of comprehensive management solutions for food and nutrition services ...

... Congress to Make Health Reform Work for ChildrenSTANFORD, Calif., ... Stanford is joining the National Association of Children,s ... grassroots mobilization campaign asking Congress and the Obama Administration ... "Our hospital is extraordinarily proud to be taking ...

... 7 MedQuist Inc., (Nasdaq: MEDQ ) a ... technology-enabled clinical documentation workflow, today announced its unaudited operating results ... the first quarter of 2009 was $6.9 million, an increase ... a loss of $4.4 million was reported. Earnings per share ...

... 7 Trey Anastasio, lead singer of the rock band ... Wednesday, May 6, to participate in a day-long celebration marking ... National Association of Drug Court Professionals (NADCP) in calling for ... Mr. Anastasio recognized over fifteen members of Congress for their ...

... statement from Georges C. Benjamin, MD, FACP, FACEP (E), ... Public Health Association (APHA) joins other leading health organizations ... Obama,s FY 2010 budget."Of particular note is the $635 ... to finance health reform and ensure that we all ...

Dr. Tanaka Appointed as Honorary Consul-General by Republic of Singapore University HealthSystem Consortium Selects Sodexo to Provide Food and Nutrition Services Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate MedQuist Reports First Quarter 2009 Results Phish Frontman Trey Anastasio Visits Capitol Hill to Support Drug Courts and Calls on Congress to Put a Drug Court Within Reach of Every American in Need APHA Applauds Health Reform Fund and Other Health Investments in Budget

(Date:5/21/2013)... Mass. , May 21, 2013 /PRNewswire/ ... research and advisory firms for pharmaceutical and ... an emerging agent on key efficacy endpoints, ... progression, has the most influence over surveyed ... advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. ...

(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ("Hurel"), ... microfluidic cell-based assay platforms, today announced the appointment of ... to the Company,s Board of Directors. Dr. MacDonald is ... the Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical ... by Merck & Co. in 2009. Over ...

(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ... BCC,s aim ... synopsis of the current and future characteristics ...

[0] Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer [0] Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)

... treating the diabetes patient, doctors discussed how a ... not enough to reveal an individual,s risk for ... Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical ... "We need to be more aggressive in treating ...

... Corporation (Nasdaq: BPUR ) announced ... U.S. Naval Medical Research Center (NMRC) by letter that it ... Hemopure(R) [hemoglobin glutamer -- 250 (bovine)] under a proposed protocol ... announced, the study, "Restore Effective Survival in Shock" (RESUS) was ...

Cached Medicine Technology:Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient 2 U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 2 U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 3

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold

Reusable Components Compatible with VERSASTEP™ Reposable Access System....

The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....

... VERSASTEP™ Plus Long Instrument for ... ,The VERSASTEP™ Plus Long Instrument ... a unique endoscopic entry device ... procedures. It is used to ...

... Step™ and Mini Step™ device components are supplied ... Single Use System is supplied sterile in 2/3, ... in various configurations and combinations. They are used ... needle and the Step™ radially Expandable Sleeve. The ...

Medicine Products:

Reusable Components VersaStep™ Reposable Powershield™ (Reusable Radiolucent Cannulae - Short Length)VersaStep™ Plus Long Instrument with 150 mm Working Length STEP™ Short Instruments